Advanced in Hyperthyroidism

Peng C. Du

Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
Advanced in Hyperthyroidism
Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Peng Du practices in Beijing, China. Mr. Du is rated as an Advanced expert by MediFind in the treatment of Hyperthyroidism. His top areas of expertise are Spinal Stenosis, Hashimoto Thyroiditis, Botulism, Vertebroplasty, and Ileostomy.

His clinical research consists of co-authoring 567 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Hyperthyroidism.

Gender
Male

Locations

Key Laboratory Of Carcinogenesis And Translational Research, Beijing, China
Other Locations
1665 Kongjiang Road, Shanghai, 200092, China
No. 1500 Zhouyuan Road, Pudong, 201318, China
No. 521 Xingnan Road, Guangzhou, 511400, China
State Key Laboratory Of Materials Oriented Chemical Engineering, Nanjing, 211816, China
1665 Kongjiang Road, Yangpu, China
No.1500 Zhouyuan Road, Pudong, 201318, China
1Department Of Neurosurgery, 324 Jingwuweiqi Road, Jinan, 250021, China
28 Fucheng Rd, Beijing, 100142, China
Fucheng Road, Haidian, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Drug
Study Phase: Phase 2

566 Total Publications

Effects of Lactobacillus helveticus KLDS 1.1105 Postbiotics and Their Exopolysaccharides on Immune Function and Gut Microbiota in Immunosuppressed Mice.
Effects of Lactobacillus helveticus KLDS 1.1105 Postbiotics and Their Exopolysaccharides on Immune Function and Gut Microbiota in Immunosuppressed Mice.
Journal: Journal of agricultural and food chemistry
Published: December 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Du's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile